Jiawei Erzhiwan improves menopausal metabolic syndrome by enhancing insulin secretion in pancreatic β cells.
10.1016/S1875-5364(16)30099-1
- Author:
Xiao-Meng WAN
1
;
Mu ZHANG
1
;
Pei ZHANG
1
;
Zhi-Shen XIE
1
;
Feng-Guo XU
1
;
Ping ZHOU
1
;
Shi-Ping MA
2
;
Xiao-Jun XU
3
,
4
Author Information
1. State Key Laboratory of Natural Medicine, China Pharmaceutical University, Nanjing 210009, China.
2. State Key Laboratory of Natural Medicine, China Pharmaceutical University, Nanjing 210009, China. Electronic address: spma2009hz@yahoo.cn.
3. State Key Laboratory of Natural Medicine, China Pharmaceutical University, Nanjing 210009, China
4. Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Nanjing 210009, China. Electronic address: xiaojunxu2000@163.com.
- Publication Type:Journal Article
- Keywords:
Estrogen receptor;
Glucose tolerance;
Islet β cell;
Jiawei Erzhiwan;
Menopausal metabolic syndrome
- MeSH:
Animals;
Drugs, Chinese Herbal;
administration & dosage;
Female;
Glucose;
metabolism;
Humans;
Insulin;
metabolism;
Insulin Secretion;
Insulin-Secreting Cells;
drug effects;
metabolism;
Menopause;
drug effects;
metabolism;
Metabolic Syndrome;
drug therapy;
metabolism;
Mice;
Rats;
Rats, Sprague-Dawley
- From:
Chinese Journal of Natural Medicines (English Ed.)
2016;14(11):823-834
- CountryChina
- Language:English
-
Abstract:
Menopausal metabolic syndrome (MMS) is a series of syndrome caused by ovarian function decline and hormone insufficiency, and is a high risk factor for cardiovascular diseases (CVD) and type II diabetes mellitus (T2DM). Erzhiwan (EZW), composed of Herba Ecliptae and Fructus Ligustri Lucidi, is a traditional Chinese herbal formula that has been used to treat menopausal syndrome for many years. We added Herba Epimedii, Radix Rehmanniae, and Fructus Corni into EZW, to prepare a new formula, termed Jiawei Erzhiwan (JE). The present study was designed to determine the anti-MMS effects of JE using ovariectomized (OVX) adult female rats that were treated with JE for 4 weeks, and β-tc-6 cells and INS cells were used to detected the protect effectiveness of JE. Our results showed JE could increase insulin sensitivity and ameliorated hyperlipidemia. Metabolomics analysis showed that the serum levels of branched and aromatic amino acids were down-regulated in serum by JE administration. Moreover, JE enhanced the function of islet β cells INS-1 and β-tc-6, through increasing the glucose stimulated insulin secretion (GSIS), which was abolished by estrogen receptor (ER) antagonist, indicating that JE functions were mediated by ER signaling. Additionally, JE did not induce tumorigenesis in rat mammary tissue or promoted proliferation of MCF-7 and Hela cells. In conclusion, our work demonstrated that JE ameliorated OVX-induced glucose and lipid metabolism disorder through activating estrogen receptor pathway and promoting GSIS in islet β cells, thus indicating that JE could be a safe and effective medication for MMS therapy.
